Navigation Links
Consult in Biological Technology

Elsevier Health Sciences Appoints Dr. David Goldmann Editor-in-Chief of its First Consult Point of Care Resource

PHILADELPHIA, Pennsylvania, May 4 /PRNewswire-FirstCall/ -- Elsevier, the leading publisher of scientific, technical and medical information, announced today that Dr. David Goldmann has joined Elsevier Health Sciences as Vice President, Editor-in-Chief, First Consult. As Editor-in-Chief, Dr. G...

Elsevier Launches Ten New eBook Specialty Collections on MD Consult

ST. LOUIS, Missouri, April 29 /PRNewswire-FirstCall/ -- - Increases Accessibility to Market-Leading Specialty Content Elsevier, the world's leading publisher of scientific, technical, and medical information products and services, announced today that ten new eBook Specialty Coll...

Madison professor emeritus will consult on development of 'Internet 2'

Madison professor emeritus Larry Landweber, who was involved in one of the first networks to use Internet technology, may lend his expertise on the next stage of the Internet, which has been proposed by the National Science Foundation. The Computer & Information Science & Engineering (CISE) br...

NeurogesX Reports Second Quarter 2009 Results

...y approval for NeurogesX' product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission. NEUROGESX, INC. ...

NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application

...y approval for NeurogesX' product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission. NeurogesX, Inc. The Ruth Group Stephen Ghiglieri ...

Exciton Technologies receives FDA approval to market exSALT(TM)

... by third parties, and the risk that the Company's patents may be subsequently shown to be invalid or infringe the patents of others. Investors should consult the Company's quarterly and annual filings with the Canadian commissions for additional information on risks and uncertainties relating to the forward...

AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

...rtunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties rel...

NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results

...y approval for NeurogesX' product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission. NeurogesX, Inc. The Ruth Group Stephen Ghiglieri ...

Oncolytics Biotech(R) Inc. Announces 2009 Second Quarter Results

... and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties rel...

Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)

...OLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties rel...

American Mothers Seriously Concerned About Childhood Allergies, Siemens Survey Reveals

...atch test (28 percent), the skin injection test (26 percent), and the skin patch test (9 percent). The top three sources mothers said they would consult for information about childhood allergies and allergy testing were: A physician or other health professional (98 percent), health/medical web sites (7...

Oncolytics Biotech(R) Inc. Completes Lyophilization Process for REOLYSIN(R)

...OLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties rel...

Oncolytics Biotech(R) Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting

... and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties rel...

AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction

...rtunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties rel...

Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial

... and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties rel...

Inverness Medical Innovations - Concateno plc, Further Announcement Regarding UK Takeover Code Share Dealing Disclosure Requirements.

...found on the Takeover Panel's website. If you are in any doubt as to whether or not you are required to disclose a "dealing" under Rule 8, you should consult the Takeover Panel whose contact details are: Tel: +44 (0) 207 638 0129; Fax +44 (0) 207 236 7013; email: info@thetakeoverpanel.org.uk " target=...

NeurogesX Added to Russell 3000 Index

...y approval for NeurogesX' product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission. NeurogesX, Inc. The Ruth Group Stephen Ghiglieri ...

Elsevier Releases Results of Alternative Energy Research Leadership Study Identifying Top 25 Institutions Worldwide

...900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect ( http://www.sciencedirect.com/ ), MD consult ( http://www.mdconsult.com/ ), Scopus ( http://www.info.scopus.com/ ), bibliographic databases, and online reference works. Elsevier ( http://...

AEterna Zentaris Receives US$10 Million from Institutional Investors

...rtunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties rel...

GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois

...s of society while continuing to contribute to the overall health and wellness of our world." The proposal calls for the CEO of Health Systems to consult with the Director of Health Systems Institutional Review Board and GeoVax to determine whether to present GeoVax's proposal to the Health Systems Boar...

AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule

...rtunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties rel...

Elsevier and NextBio Sign Partnership to Enrich ScienceDirect Content, Accelerating Life Sciences, Health Sciences and Chemistry Research

...900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect ( http://www.sciencedirect.com/ ), MD consult ( http://www.mdconsult.com/ ), Scopus ( http://www.info.scopus.com/ ), bibliographic databases, and online reference works. Elsevier ( http://...

NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)

...y approval for NeurogesX' product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission. NeurogesX, Inc. The Ruth Group Stephen Ghiglieri ...

AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia

...rtunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties rel...

Elsevier / MC Strategies Online Courses Named in the 15th Annual Communicator Awards

...900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect ( http://www.sciencedirect.com/ ), MD consult ( http://www.mdconsult.com/ ), Scopus ( http://www.info.scopus.com/ ), bibliographic databases, and online reference works. Elsevier ( http://...

AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer

...rtunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties rel...

AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130

...rtunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties rel...

ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema

...rtant to investors in the investor relations and media sections of our company's web site, www.viropharma.com . The company encourages investors to consult these sections for more information on ViroPharma and our business. Forward-Looking Statements Certain statements in this press release conta...

NeurogesX to Present at Needham Life Sciences Conference

...product candidates over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission. NeurogesX, Inc. The Ruth Group Stephen Ghiglieri ...

Cell Therapeutics Amends and Restates Its 'Modified Dutch Auction' Tender Offer to a Fixed Price Tender Offer for Any and All of Its $118.9 Million Outstanding Convertible Notes

...ld carefully evaluate all of the information in the Exchange Offer Documents before making any decision with respect to the Exchange Offers and should consult their own investment and tax advisors. Holders of the Notes who have questions or would like additional copies of the Exchange Offer Documents ma...

ViroPharma to Present at Two June Healthcare Conferences

...rtant to investors in the investor relations and media sections of our company's web site, www.viropharma.com . The company encourages investors to consult these sections for more information on ViroPharma and our business. ...

Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting

... and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties rel...

AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting

...rtunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties rel...

Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452

...llaboration agreements with such partners. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission. CONTACT: Cytokinetics, South San Francisco Chris Keenan, Director Inv...

Elsevier's Science & Technology Division and Science News Partner to Organize the First "Attracting Academic Talent Summit" in Beijing

...900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect ( http://www.sciencedirect.com/ ), MD consult ( http://www.mdconsult.com/ ), Scopus ( http://www.info.scopus.com/ ), bibliographic databases, and online reference works. Elsevier ( http://...

NeurogesX Receives European Commission Approval for Qutenza(TM)

...product candidates over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission. NeurogesX, Inc. Stephen Ghiglieri Chief Financial Officer (650)...

AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting

...rtunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties rel...

Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD

... number of patients, particularly when ASMANEX is administered at higher than recommended doses over prolonged periods of time. If such effects occur, consult your health care provider as the dosage of ASMANEX should be reduced slowly. If you or your child took steroids by mouth and are having them decr...

Cell Therapeutics Amends 'Modified Dutch Auction' Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes

...uld carefully evaluate all of the information in the Exchange Offer Documents before making any decision with respect to the Exchange Offer and should consult their own investment and tax advisors. Holders of the Notes who have questions or would like additional copies of the Exchange Offer documents ma...

ViroPharma Incorporated Honored by the National Organization for Rare Disorders

...rtant to investors in the investor relations and media sections of our company's web site, www.viropharma.com . The company encourages investors to consult these sections for more information on ViroPharma and our business. Forward-Looking Statements Certain statements in this press release ...
Other Tags
(Date:7/28/2014)... became the first man to reach the South Pole ... an international team of scientists led by Joe McConnell ... air pollution from industrial activities arrived long before. , ... spaced locations around the Antarctic continent, including the South ... reconstruction to date of lead pollution over the Earth,s ...
(Date:7/27/2014)... largest prevalence studies to date, researchers from the U.K. ... the hepatitis C virus (HCV). Findings published in Hepatology, ... of Liver Diseases, indicate that genotype 1 is the ... of which one-third reside in East Asia. Genotype 3, ... most prevalent, followed by genotypes 2, 4, 6, and ...
(Date:7/27/2014)... shown the potential for global climate change to cut ... part, ignored the interactions between increasing temperature and air ... damage crops. , A new study involving researchers at ... suggesting that policymakers need to take both warming and ... The study looked in detail at global production of ...
Breaking Biology News(10 mins):Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3Hepatitis C virus genotype 1 is most prevalent worldwide 2Study: Climate change and air pollution will combine to curb food supplies 2Study: Climate change and air pollution will combine to curb food supplies 3
(Date:7/28/2014)... St. Jude Children’s Research Hospital ... of Defense Employer Support Freedom Award from the Employer Support ... Defense. The award is the highest honor given by the ... who serve in the National Guard and Reserve. , “We ... their contributions to the St. Jude mission and to our ...
(Date:7/28/2014)... possible by a test developed at University of Colorado ... of Pharmacy), AURORA, Colo (July 28, 2014) An influential ... Pharmacology Laboratory at the CU School of Pharmacy, helps ... Truvada (a combination of tenofovir/emtricitabine), which is taken once ... presented during the AIDS 2014 Conference and published in ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 The ... Lipase), Applications (Food & Beverages, Cleaning Agents, Bio-Fuel, ... Forecasts to 2018” defines and segments the global ... the global value for industrial enzymes. It also ... industrial enzymes market with analysis of trends, opportunities, ...
(Date:7/28/2014)... 2014 Qualis Health, one of ... organizations, has published a complimentary, online toolkit that ... patients and families in infection control. Tested ... the toolkit provides a step-by-step roadmap for implementing ... their families early in a hospital stay. , ...
(Date:7/28/2014)... Dennis Thompson HealthDay ... -- Babies born prematurely appear to have a slightly ... will carry into adulthood, Swedish researchers report. Doctors ... weeks, gestation have a raised risk of deep vein ... blood clotting in the veins, the researchers noted in ...
Breaking Medicine News(10 mins):Health News:St. Jude Children’s Research Hospital Receives Secretary of Defense Employer Support Freedom Award 2Health News:St. Jude Children’s Research Hospital Receives Secretary of Defense Employer Support Freedom Award 3Health News:HIV research findings made possible by a test developed at CU School of Pharmacy 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:Patient Engagement in Hospital Infection Control: Online Toolkit Provides a New Solution 2Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 2Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 3
Other Contents